Humanized antibodies to LIV-1 and use of same to treat cancer
US9228026B2 · kind B2 · utility
6Cited by
12References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 6, 2011 |
| Grant date | Jan 5, 2016 |
| Priority date | — |
| Expiry date | Aug 20, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides humanized antibodies that specifically bind to LIV-1. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting LIV-1.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.